Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? Although we confess that it may be hard to tell, given how the days tend to blur together lately. Nonetheless, we will take a moment to indulge in weekend daydreams. Our agenda is, not surprisingly, modest. We intend to spend time in the yard, take a nap, and promenade with the mascot, although we are still trying to fashion a mask that sufficiently covers snouts. And what about you? This is a fine time to take a stroll — exercise is more important than ever. You could binge watch on the telly. Or touch base with someone who needs a little human contact. Well, whatever you do, keep on the sunny side. Enjoy, but be safe. See you soon. …

After preliminary positive results of a U.S. trial of remdesivir, the experimental Gilead Sciences (GILD) drug for Covid-19, the company now faces the challenge of scaling up production of a drug the whole world may want, STAT explains. But some of the substances used to make remdesivir are scarce, and the company wants to be careful not to disrupt its own supply chain. “You don’t just turn a dial and say, ‘Hey, we’re going to start making this,’” says Bernhardt Trout, a professor of chemical engineering at the Massachusetts Institute of Technology.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy